Karyopharm Therapeutics Investor Presentation — December 2020

Document content

December 8, 2020Investor Conference Call:

American Society of Hematology (ASH) 20202 ©2020 Karyopharm Therapeutics Inc. Forward- looking Statements and Other Important Information

This presentation contains forward -looking statements within themeaning ofThePrivate Securities Litigation Reform Actof1995 .Such forward -looking statements include those

regarding Karyopharm’s expectations andplans relating toXPOVIO forthetreatment ofpatients withrelapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large

B-celllymphoma ;commercialization ofXPOVIO oranyofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval of

selinexor by,regulatory authorities, including theCompany's regulatory strategy, theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions and

actions byregulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected design oftheCompany's clinical trials ;thetherapeutic potential ofand

potential clinical development plans forKaryopharm's drug candidates, especially selinexor .Such statements aresubject tonumerous important factors, risks anduncertainties,

many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample, there canbeno

guarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators willagree thatselinexor qualifies forconditional approval intheE.U.asaresult ofdata from

theSTORM study orconfirmatory approval intheU.S.orE.U.based ontheBOSTON study inpatients with multiple myeloma orthat anyofKaryopharm's drug candidates,